CN1261149C - Medicine for treating rheumatoid arthritis, femur necrosis and ankylosing spondylitis - Google Patents
Medicine for treating rheumatoid arthritis, femur necrosis and ankylosing spondylitis Download PDFInfo
- Publication number
- CN1261149C CN1261149C CN 200410060534 CN200410060534A CN1261149C CN 1261149 C CN1261149 C CN 1261149C CN 200410060534 CN200410060534 CN 200410060534 CN 200410060534 A CN200410060534 A CN 200410060534A CN 1261149 C CN1261149 C CN 1261149C
- Authority
- CN
- China
- Prior art keywords
- portions
- radix
- rhizoma
- fructus
- parched
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a medicine for treating rheumatoid arthritis, femoral head necrosis and ankylosing spondylitis. The present invention is basically formed by combining raw materials in the following mixing proportions (portions by weight): 18 portions of astragalus roots, 6 portions of cortex magnoliae officinalis from Sichuan of China, 15 portions of chickens' gizzard-membranes, 15 portions of coloured malt, 6 portions of amomum fruits, 6 portions of dried orange peels, 15 portions of medicated leaven, 20 portions of roots of straight ladybell from Liaoning of China, 8 portions of Chinese angelica roots, 8 portions of hemlock parsley, 12 portions of poria from Yunnan of China, 10 portions of stir-fried fructus aurantii immaturus, 6 portions of Chinese atractylodes, 10 portions of astraolylis lancea formalyrata, 18 portions of pearl barley, 6 portions of gentiana macrophylla, 6 portions of yams, 6 portions of radix sileris, 6 portions of rhizoma corydalis, 8 portions of common fennel, 10 portions of Jiazhu, 6 portions of Zaoci, 15 portions of fresh oyster shells, 12 portions of drynaria, 6 portions of buck grass, 6 portions of bupleurum roots, 3 portions of cimicifuga foetida and 8 portions of achyranthes roots. The present invention has the advantages of symptom relieving and pathogenetic condition inhibition. The present invention improves a patient's immune function, metabolism unction and internal organ function to achieve the purpose of healing without relapse. The patient treated by adopting the Chinese medicine does not need to take an antiinflammatory pain-relieving medicine without body fluid extraction nor restoration operation.
Description
Technical field
The present invention relates to a kind of Chinese medicine, especially relate to a kind of medicine for the treatment of rheumatoid arthritis, femur head necrosis, ankylosing spondylitis.
Background technology
Generally all adopt high antiinflammatory, high analgesic medicine, cooperate injection anesthesia needle, hormonal medicaments to treat for diseases such as rheumatoid arthritis, femur head necrosis, ankylosing spondylitises at present.From present therapeutic outcome, control disease often and do not cure the disease, only play the effect of relief of symptoms, and sclerotin is still in pathological changes, therapeutic effect is undesirable, has often incured loss through delay the state of an illness, finally causes adopting operating Therapeutic Method, causes patient maimed person.
Summary of the invention
The objective of the invention is provides a kind of medicine for the treatment of rheumatoid arthritis, femur head necrosis, ankylosing spondylitis at above-mentioned existing in prior technology deficiency.
For achieving the above object, the present invention can take following technical proposals:
The medicine of treatment rheumatoid arthritis of the present invention, femur head necrosis, ankylosing spondylitis, it is combined by following proportioning raw materials (weight portion):
Radix Astragali 18-20, Cortex Magnoliae Officinalis 6-15, Endothelium Corneum Gigeriae Galli 15-20, Fructus Hordei Germinatus (parched) 15-30, Fructus Amomi 6-15, Pericarpium Citri Reticulatae 6-15, Massa Medicata Fermentata 15-20, RADIX GLEHNIAE from Liaoning of China 20-30, Radix Angelicae Sinensis 8-15, Rhizoma Chuanxiong 8-15, Poria 12-15, Fructus Aurantii (parched) 10-15, Rhizoma Atractylodis 6-10, Rhizoma Atractylodis Macrocephalae 10-18, Semen Coicis 18-30, Radix Gentianae Macrophyllae 6-10, Rhizoma Dioscoreae Nipponicae 6-10, Radix Saposhnikoviae 6-15, Rhizoma Corydalis 6-20, Fructus Foeniculi 8-15, Squama Manis 10-15, Spina Gleditsiae 6-10, Concha Ostreae 15-30, Rhizoma Drynariae 12-15, Herba Lycopodii 6-10, Radix Bupleuri 6-10, Rhizoma Cimicifugae 3-6, Radix Achyranthis Bidentatae 8-12.
Medicine of the present invention can combine by following proportioning raw materials (weight portion):
The Radix Astragali 18, Cortex Magnoliae Officinalis 6, Endothelium Corneum Gigeriae Galli 15, Fructus Hordei Germinatus (parched) 15, Fructus Amomi 6, Pericarpium Citri Reticulatae 6, Massa Medicata Fermentata 15, RADIX GLEHNIAE from Liaoning of China 20, Radix Angelicae Sinensis 8, Rhizoma Chuanxiong 8, Poria 12, Fructus Aurantii (parched) 10, Rhizoma Atractylodis 6, the Rhizoma Atractylodis Macrocephalae 10, Semen Coicis 18, Radix Gentianae Macrophyllae 6, Rhizoma Dioscoreae Nipponicae 6, Radix Saposhnikoviae 6, Rhizoma Corydalis 6, Fructus Foeniculi 8, Squama Manis 10, Spina Gleditsiae 60, Concha Ostreae 15, Rhizoma Drynariae 12, Herba Lycopodii 6, Radix Bupleuri 6, Rhizoma Cimicifugae 3, Radix Achyranthis Bidentatae 8.
Medicine of the present invention also can combine by following proportioning raw materials (weight portion):
The Radix Astragali 19, Cortex Magnoliae Officinalis 11, Endothelium Corneum Gigeriae Galli 18, Fructus Hordei Germinatus (parched) 22, Fructus Amomi 9, Pericarpium Citri Reticulatae 10, Massa Medicata Fermentata 18, RADIX GLEHNIAE from Liaoning of China 25, Radix Angelicae Sinensis 11, Rhizoma Chuanxiong 12, Poria 14, Fructus Aurantii (parched) 13, Rhizoma Atractylodis 8, the Rhizoma Atractylodis Macrocephalae 15, Semen Coicis 25, Radix Gentianae Macrophyllae 8, Rhizoma Dioscoreae Nipponicae 7, Radix Saposhnikoviae 12, Rhizoma Corydalis 12, Fructus Foeniculi 11, Squama Manis 13, Spina Gleditsiae 8, Concha Ostreae 23, Rhizoma Drynariae 13, Herba Lycopodii 8, Radix Bupleuri 8, Rhizoma Cimicifugae 5, Radix Achyranthis Bidentatae 10.
Medicine of the present invention also can combine by following proportioning raw materials (weight portion):
The Radix Astragali 20, Cortex Magnoliae Officinalis 15, Endothelium Corneum Gigeriae Galli 20, Fructus Hordei Germinatus (parched) 30, Fructus Amomi 15, Pericarpium Citri Reticulatae 15, Massa Medicata Fermentata 20, RADIX GLEHNIAE from Liaoning of China 30, Radix Angelicae Sinensis 15, Rhizoma Chuanxiong 15, Poria 15, Fructus Aurantii (parched) 15, Rhizoma Atractylodis 10, the Rhizoma Atractylodis Macrocephalae 18, Semen Coicis 30, Radix Gentianae Macrophyllae 10, Rhizoma Dioscoreae Nipponicae 10, Radix Saposhnikoviae 15, Rhizoma Corydalis 20, Fructus Foeniculi 15, Squama Manis 15, Spina Gleditsiae 10, Concha Ostreae 30, Rhizoma Drynariae 15, Herba Lycopodii 10, Radix Bupleuri 10, Rhizoma Cimicifugae 6, Radix Achyranthis Bidentatae 12.
The invention has the advantages that relief of symptoms, suppress the state of an illness, improve patient immune function, metabolic function and internal organs function, do not recur purpose to reach healing.Adopt this treatment by Chinese herbs to need not to take anti-inflammation analgesis medicament, drawing liquid is not done repairing operation.With first, the different state of an illness of intermediary and later stages, general through individual month the function that can recover the patient course of treatment of 1-5, when enhance immunity, balance metabolism, removing wind-damp dispelling, Repercusion analgesia, the high erythrocyte sedimentation rate of change rheumatoid arthritis that can be stable, the positive factor of rheumatoid, lupus erythematosus cell (LE cell), goat hyperuricemia suppress, get rid of goat.Medicine of the present invention is a decoction, also can make electuary, pill according to a conventional method.
Chinese medicine clinical treatment statistics case of the present invention sees the following form:
Rheumatoid arthritis:
The treatment number: 375 people, wherein: man, 203 people; The woman, 172 people.
Patient age: 10-20 year, 145 people; 20-40 year, 161 people; More than 40 years old, 69 people.
Medical history: 1-3,205 people; 3-5,95 people; 5-10,72 people; More than 10 years, 3 people.
Cured 165 people the course of treatment: 1-3 month; 3-5 month, 173 people; More than 5 months, 37 people.
Ischemia femur head necrosis:
Treatment number: 32 people.
Patient age: 10-20 year, 11 people; 20-40 year, 15 people; More than 40 years old, 6 people.
Medical history: 1-3,15 people; 3-5,13 people; 5-10,4 people.
Cured 19 people the course of treatment: 3-5 month; More than 5 months, 13 people.
Ankylosing spondylitis:
Treatment number: 38 people.
Patient age: 10-20 year, 5 people; 20-40 year, 21 people; More than 40 years old, 12 people.
Medical history: 1-3,19 people; 3-5,12 people; 5-10,7 people.
Cured 28 people the course of treatment: 3-5 month; More than 5 months, 10 people.
The specific embodiment
Embodiment 1:
Medicine of the present invention is combined by following proportioning raw materials (weight portion):
The Radix Astragali 18, Cortex Magnoliae Officinalis 6, Endothelium Corneum Gigeriae Galli 15, Fructus Hordei Germinatus (parched) 15, Fructus Amomi 6, Pericarpium Citri Reticulatae 6, Massa Medicata Fermentata 15, RADIX GLEHNIAE from Liaoning of China 20, Radix Angelicae Sinensis 8, Rhizoma Chuanxiong 8, Poria 12, Fructus Aurantii (parched) 10, Rhizoma Atractylodis 6, the Rhizoma Atractylodis Macrocephalae 10, Semen Coicis 18, Radix Gentianae Macrophyllae 6, Rhizoma Dioscoreae Nipponicae 6, Radix Saposhnikoviae 6, Rhizoma Corydalis 6, Fructus Foeniculi 8, Squama Manis 10, Spina Gleditsiae 60, Concha Ostreae 15, Rhizoma Drynariae 12, Herba Lycopodii 6, Radix Bupleuri 6, Rhizoma Cimicifugae 3, Radix Achyranthis Bidentatae 8.
Embodiment 2:
Medicine of the present invention is combined by following proportioning raw materials (weight portion):
The Radix Astragali 19, Cortex Magnoliae Officinalis 11, Endothelium Corneum Gigeriae Galli 18, Fructus Hordei Germinatus (parched) 22, Fructus Amomi 9, Pericarpium Citri Reticulatae 10, Massa Medicata Fermentata 18, RADIX GLEHNIAE from Liaoning of China 25, Radix Angelicae Sinensis 11, Rhizoma Chuanxiong 12, Poria 14, Fructus Aurantii (parched) 13, Rhizoma Atractylodis 8, the Rhizoma Atractylodis Macrocephalae 15, Semen Coicis 25, Radix Gentianae Macrophyllae 8, Rhizoma Dioscoreae Nipponicae 7, Radix Saposhnikoviae 12, Rhizoma Corydalis 12, Fructus Foeniculi 11, Squama Manis 13, Spina Gleditsiae 8, Concha Ostreae 23, Rhizoma Drynariae 13, Herba Lycopodii 8, Radix Bupleuri 8, Rhizoma Cimicifugae 5, Radix Achyranthis Bidentatae 10.
Embodiment 3:
Medicine of the present invention is combined by following proportioning raw materials (weight portion):
The Radix Astragali 20, Cortex Magnoliae Officinalis 15, Endothelium Corneum Gigeriae Galli 20, Fructus Hordei Germinatus (parched) 30, Fructus Amomi 15, Pericarpium Citri Reticulatae 15, Massa Medicata Fermentata 20, RADIX GLEHNIAE from Liaoning of China 30, Radix Angelicae Sinensis 15, Rhizoma Chuanxiong 15, Poria 15, Fructus Aurantii (parched) 15, Rhizoma Atractylodis 10, the Rhizoma Atractylodis Macrocephalae 18, Semen Coicis 30, Radix Gentianae Macrophyllae 10, Rhizoma Dioscoreae Nipponicae 10, Radix Saposhnikoviae 15, Rhizoma Corydalis 20, Fructus Foeniculi 15, Squama Manis 15, Spina Gleditsiae 10, Concha Ostreae 30, Rhizoma Drynariae 15, Herba Lycopodii 10, Radix Bupleuri 10, Rhizoma Cimicifugae 6, Radix Achyranthis Bidentatae 12.
Claims (4)
1, a kind of medicine for the treatment of rheumatoid arthritis, femur head necrosis, ankylosing spondylitis, it is characterized in that: it is combined by the following raw materials in parts by weight proportioning:
Radix Astragali 18-20, Cortex Magnoliae Officinalis 6-15, Endothelium Corneum Gigeriae Galli 15-20, Fructus Hordei Germinatus (parched) 15-30, Fructus Amomi 6-15, Pericarpium Citri Reticulatae 6-15, Massa Medicata Fermentata 15-20, RADIX GLEHNIAE from Liaoning of China 20-30, Radix Angelicae Sinensis 8-15, Rhizoma Chuanxiong 8-15, Poria 12-15, Fructus Aurantii (parched) 10-15, Rhizoma Atractylodis 6-10, Rhizoma Atractylodis Macrocephalae 10-18, Semen Coicis 18-30, Radix Gentianae Macrophyllae 6-10, Rhizoma Dioscoreae Nipponicae 6-10, Radix Saposhnikoviae 6-15, Rhizoma Corydalis 6-20, Fructus Foeniculi 8-15, Squama Manis 10-15, Spina Gleditsiae 6-10, Concha Ostreae 15-30, Rhizoma Drynariae 12-15, Herba Lycopodii 6-10, Radix Bupleuri 6-10, Rhizoma Cimicifugae 3-6, Radix Achyranthis Bidentatae 8-12.
2, medicine according to claim 1 is characterized in that: it is combined by the following raw materials in parts by weight proportioning:
The Radix Astragali 18, Cortex Magnoliae Officinalis 6, Endothelium Corneum Gigeriae Galli 15, Fructus Hordei Germinatus (parched) 15, Fructus Amomi 6, Pericarpium Citri Reticulatae 6, Massa Medicata Fermentata 15, RADIX GLEHNIAE from Liaoning of China 20, Radix Angelicae Sinensis 8, Rhizoma Chuanxiong 8, Poria 12, Fructus Aurantii (parched) 10, Rhizoma Atractylodis 6, the Rhizoma Atractylodis Macrocephalae 10, Semen Coicis 18, Radix Gentianae Macrophyllae 6, Rhizoma Dioscoreae Nipponicae 6, Radix Saposhnikoviae 6, Rhizoma Corydalis 6, Fructus Foeniculi 8, Squama Manis 10, Spina Gleditsiae 6, Concha Ostreae 15, Rhizoma Drynariae 12, Herba Lycopodii 6, Radix Bupleuri 6, Rhizoma Cimicifugae 3, Radix Achyranthis Bidentatae 8.
3, medicine according to claim 1 is characterized in that: it is combined by the following raw materials in parts by weight proportioning:
The Radix Astragali 19, Cortex Magnoliae Officinalis 11, Endothelium Corneum Gigeriae Galli 18, Fructus Hordei Germinatus (parched) 22, Fructus Amomi 9, Pericarpium Citri Reticulatae 10, Massa Medicata Fermentata 18, RADIX GLEHNIAE from Liaoning of China 25, Radix Angelicae Sinensis 11, Rhizoma Chuanxiong 12, Poria 14, Fructus Aurantii (parched) 13, Rhizoma Atractylodis 8, the Rhizoma Atractylodis Macrocephalae 15, Semen Coicis 25, Radix Gentianae Macrophyllae 8, Rhizoma Dioscoreae Nipponicae 7, Radix Saposhnikoviae 12, Rhizoma Corydalis 12, Fructus Foeniculi 11, Squama Manis 13, Spina Gleditsiae 8, Concha Ostreae 23, Rhizoma Drynariae 13, Herba Lycopodii 8, Radix Bupleuri 8, Rhizoma Cimicifugae 5, Radix Achyranthis Bidentatae 10.
4, medicine according to claim 1 is characterized in that: it is combined by the following raw materials in parts by weight proportioning:
The Radix Astragali 20, Cortex Magnoliae Officinalis 15, Endothelium Corneum Gigeriae Galli 20, Fructus Hordei Germinatus (parched) 30, Fructus Amomi 15, Pericarpium Citri Reticulatae 15, Massa Medicata Fermentata 20, RADIX GLEHNIAE from Liaoning of China 30, Radix Angelicae Sinensis 15, Rhizoma Chuanxiong 15, Poria 15, Fructus Aurantii (parched) 15, Rhizoma Atractylodis 10, the Rhizoma Atractylodis Macrocephalae 18, Semen Coicis 30, Radix Gentianae Macrophyllae 10, Rhizoma Dioscoreae Nipponicae 10, Radix Saposhnikoviae 15, Rhizoma Corydalis 20, Fructus Foeniculi 15, Squama Manis 15, Spina Gleditsiae 10, Concha Ostreae 30, Rhizoma Drynariae 15, Herba Lycopodii 10, Radix Bupleuri 10, Rhizoma Cimicifugae 6, Radix Achyranthis Bidentatae 12.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410060534 CN1261149C (en) | 2004-09-23 | 2004-09-23 | Medicine for treating rheumatoid arthritis, femur necrosis and ankylosing spondylitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410060534 CN1261149C (en) | 2004-09-23 | 2004-09-23 | Medicine for treating rheumatoid arthritis, femur necrosis and ankylosing spondylitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1634311A CN1634311A (en) | 2005-07-06 |
| CN1261149C true CN1261149C (en) | 2006-06-28 |
Family
ID=34846253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410060534 Expired - Fee Related CN1261149C (en) | 2004-09-23 | 2004-09-23 | Medicine for treating rheumatoid arthritis, femur necrosis and ankylosing spondylitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1261149C (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101015682B (en) * | 2007-02-01 | 2011-02-02 | 兰州奇正健康日用品有限公司 | Medicine composition with compact bone substance density improving function, preparing process and quality controlling means thereof |
| CN102441154B (en) * | 2011-11-23 | 2016-05-04 | 朱法存 | A kind of Chinese medicine preparation for the treatment of gout |
| CN103919965A (en) * | 2014-04-30 | 2014-07-16 | 蚌埠明日欣医药有限公司 | Traditional Chinese medicine mixture for treating ankylosing spondylitis |
| CN105920264A (en) * | 2016-04-27 | 2016-09-07 | 石良 | Ankylosing spondylitis rehabilitation pill as well as preparation method and taking method thereof |
| CN106039223A (en) * | 2016-07-14 | 2016-10-26 | 路杨景 | Traditional Chinese medicine composition for treating arthropathy and manufacturing method of Traditional Chinese medicine composition pills |
| JP6961020B2 (en) * | 2017-06-13 | 2021-11-05 | 首都医科大学附属北京地壇医院 | Use of Drosophila Triterpenoid Saponins Extract, Actane, Deoxy Actane |
-
2004
- 2004-09-23 CN CN 200410060534 patent/CN1261149C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1634311A (en) | 2005-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1091609C (en) | Tincture for treating rheumatoid arthritis and its preparing process | |
| CN1261149C (en) | Medicine for treating rheumatoid arthritis, femur necrosis and ankylosing spondylitis | |
| CN1554413A (en) | Chinese medicine for treating urolithiasis and its preparing method | |
| CN1332702C (en) | Medicine for treating psoriasis | |
| CN1261139C (en) | Medicine for treating bone tuberculosis, osteomyelitis, synovitis and angeitis | |
| CN1141114C (en) | Tendon-conditioning analgetic | |
| CN1698863A (en) | Chinese medicinal preparation for treating hyperosteogeny | |
| CN1136899C (en) | Chinese medicine for treating mastoplasia | |
| CN1199685C (en) | Medicine for treating upper respiratory tract infection type cold | |
| CN107753700A (en) | A kind of medicine for treating chronic hepatitis | |
| CN1244370C (en) | Medicinal composition for curing skin disease | |
| CN1272060C (en) | Medicine for preventing apoplexy and its preparation method | |
| CN1277577C (en) | Chinese traditional medicine for treating cerebral thrombosis, preparation method and application | |
| CN1289611A (en) | Quick-acting Chinese medicine for treating cirrhosis and its preparing process | |
| CN1113804A (en) | Antianemic powder and its preparing method | |
| CN1872255A (en) | Oral liquid for apoplexia | |
| CN1161135C (en) | Medicine for curing carcinoma of stomach | |
| CN1043458C (en) | Traditional Chinese medicine powder for curing hepatitis, cirrhosis and hepatonecrosis | |
| CN1036503C (en) | Medicine for treating systemic lupus erythematosus and producing method thereof | |
| CN1167433C (en) | Medicine for treating acne and its preparing process | |
| CN101036742A (en) | Medicine for treating prostatic disease | |
| CN1163136A (en) | Medicine for curing stone in urinary system | |
| CN1883691A (en) | Medicine for treating mammary glands hyperplasia | |
| CN1907396A (en) | Medicine for treating cerebral hemorrhage | |
| CN1253161C (en) | Medicine for treating cerebrovascular disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |